RECURRENT CHILDHOOD RHABDOMYOSARCOMA
Clinical trials for RECURRENT CHILDHOOD RHABDOMYOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHILDHOOD RHABDOMYOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHILDHOOD RHABDOMYOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with resistant cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…
Matched conditions: RECURRENT CHILDHOOD RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Gene test trial aims to personalize cancer care for kids
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…
Matched conditions: RECURRENT CHILDHOOD RHABDOMYOSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 07:04 UTC